

Supplementary information

Silencing-mediated enhancement of osteogenic differentiation by supramolecular ternary siRNA polyplexes comprising biocleavable cationic polyrotaxanes and anionic fusogenic peptides

Takasuke Inada¹, Atsushi Tamura^{2,*}, Masahiko Terauchi^{1,2}, Satoshi Yamaguchi¹, Nobuhiko Yui²

¹Department of Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo, Tokyo 113-8549, Japan.

²Department of Organic Biomaterials, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU), 2-3-10 Kanda-Surugadai, Chiyoda, Tokyo 101-0062, Japan.

*Corresponding author: A. Tamura (E-mail address: tamura.org@tmd.ac.jp)

Table of contents

- S1. Characterization of DMAE-SS-PRX
- S2. Stability of the complexes against polyanion exchange reaction
- S3. Cell viability
- S4. Reference

S1. Characterization of DMAE-SS-PRX. DMAE-SS-PRX composed of *N,N*-dimethylaminoethyl carbamate (DMAE)-modified α -CDs as a cyclic molecule, cystamine-conjugated PEG (H_2N -SS-PEG-SS- NH_2 , $M_n = 4,910$, $M_w/M_n = 1.13$, degree of polymerization = 103) as an axle polymer, and *N*-carbobenzoxy-L-tyrosine as a stopper molecule was synthesized according to our previous report.¹ ^1H nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Avance III 400 MHz spectrometer (Bruker BioSpin, Rheinstetten, Germany). The number of threading α -CDs in the PRX was calculated from the peak area between 3.1-4.0 ppm ($-\text{O}-\text{CH}_2-\text{CH}_2-\text{O}-$ of PEG axle and H_2 , H_3 , H_4 , H_5 , and H_6 protons of the threaded α -CD) and 4.77-4.95 ppm (H_1 proton of the threaded α -CD) in the ^1H NMR spectrum of unmodified PRX (Fig. S1A). The number of DMAE groups modified onto the DMAE-SS-PRX was calculated from the peak area between 3.2 ppm ($-\text{NH}-\text{CH}_2-\text{CH}_2-\text{N}(\text{CH}_3)_2$ of the DMAE carbamate) and 4.8-5.3 ppm (H_1 proton of the threaded α -CD) in the ^1H NMR spectrum of DMAE-SS-PRX (Fig. S1B). The number of threading α -CDs and the number of modified DMAE groups in DMAE-SS-PRX were determined to be 21.9 and 78.0, respectively. The $M_{n,\text{NMR}}$ of DMAE-SS-PRX was calculated to be 36,500 based on the numbers of threaded α -CDs and DMAE groups determined by ^1H NMR.

S2. Stability of the complexes against polyanion exchange reaction. The stability of the DMAE-PRX/siRNA polyplexes and GALA/DMAE-SS-PRX/siRNA ternary polyplexes against polyanion exchange reaction was evaluated by gel electrophoresis.¹ In this experiment, heparin (Sigma-Aldrich, Milwaukee, WI, USA) was used as the polyanion. The DMAE-PRX/siRNA polyplex (N/P 10) and GALA/DMAE-SS-PRX/siRNA ternary polyplex solutions (N/P 10, Glu/P 0.2) were mixed with heparin solutions at various concentrations (1 to 1,000 $\mu\text{g/mL}$) (final siRNA concentration was 2.5 μM). The resulting solution was incubated at 37 $^\circ\text{C}$ for 1 h. Electrophoresis was then performed on a 2% agarose gel in TAE buffer (40 mM Tris, 20 mM acetic acid, and 1 mM EDTA) at 100 V for 10 min.

S3. Cell viability. MC3T3-E1 cells were plated in a 96-well plate at a density of 2.5×10^4 cells/cm² and incubated overnight. After the medium was replaced with fresh medium (90 μ L), the treatment solutions (10 μ L) were added and incubated for 48 h. For determining cell viability, Cell Counting Kit-8 reagent (Dojindo Laboratories, Kumamoto, Japan) (10 μ L) was added to each well. After incubation for 1 h at 37 °C, the absorbance at 450 nm was measured using a Multiskan FC plate reader (Thermo Fisher Scientific, Waltham, MA, USA). The cellular viability was calculated relative to the untreated cells.

S4. Reference

1. A. Tamura and N. Yui, *Biomaterials*, 2013, **34**, 2480–2491.




Figure S1. ¹H NMR spectra of unmodified PRX in NaOD/D₂O (A) and DMAE-SS-PRX in D₂O (B).




Figure S2. Release of siRNA from DMAE-SS-PRX/siRNA polyplex (N/P 10) and GALA/DMAE-SS-PRX/siRNA ternary polyplex (N/P 10, Glu/P 0.2) by the polyanion exchange with heparin.




Figure S3. Viability of MC3T3-E1 cells treated with DMAE-SS-PRX/siRNA polyplex (N/P 10) and GALA/DMAE-SS-PRX/siRNA ternary polyplex (N/P 10, Glu/P 0.2) at various concentration of siRNA for 48 h. Data are expressed as the mean \pm standard deviation (n = 5).